A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs AMC 303 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors amcure
- 14 Oct 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Clinical study design was presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to an amcure media release.